REPROCELL Launches StemEdit – Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools

2026-01-28 - 16:03

BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ — REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1TM, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready